SciSparc Ltd. (SPRC)
NASDAQ: SPRC · Real-Time Price · USD
5.13
-0.72 (-12.31%)
At close: Sep 3, 2026, 4:00 PM EDT
5.18
+0.05 (0.97%)
After-hours: Sep 3, 2026, 7:30 PM EDT
SciSparc Employees
SciSparc had 3 employees as of December 31, 2025. The number of employees increased by 1 or 50.00% compared to the previous year.
Employees
3
Change (1Y)
1
Growth (1Y)
50.00%
Revenue / Employee
$285,333
Profits / Employee
-$4,059,667
Market Cap
2.98M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 3 | 1 | 50.00% |
| Dec 31, 2024 | 2 | -1 | -33.33% |
| Dec 31, 2023 | 3 | 0 | - |
| Dec 31, 2022 | 3 | 0 | - |
| Dec 31, 2021 | 3 | 1 | 50.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Valion Bio | 52 |
| Aptevo Therapeutics | 33 |
| Calidi Biotherapeutics | 29 |
| Curis | 24 |
| Genprex | 13 |
| Artelo Biosciences | 7 |
| Jupiter Neurosciences | 5 |
| 60 Degrees Pharmaceuticals | 3 |
SPRC News
- 1 day ago - SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies - TheNewswire
- 1 day ago - SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies - TheNewswire
- 3 days ago - SciSparc subsidiary provides update on SCI-210 trial enrollment - TheFly
- 3 days ago - SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial - GlobeNewsWire
- 3 days ago - NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial - TheNewswire
- 6 days ago - Neurothera Labs Inc. Announces Share Consolidation - TheNewswire
- 7 days ago - Psychedelic: SciSparc, Clearmind publish patent application for PTSD treatment - TheFly
- 7 days ago - NeuroThera Labs Engages Dr. Reuter Investor Relations - TheNewswire